BRCA1 and BRCA2 Gene Mutations and Lung Cancer Sisk: A Meta-Analysis.

Szczegóły
Abstrakt

Tytuł:: BRCA1 and BRCA2 Gene Mutations and Lung Cancer Sisk: A Meta-Analysis.
Autorzy:: Lee YC; Department of Oncology, Tainan Hospital, Ministry of Health and Welfare, Tainan 700, Taiwan.; Department of Internal Medicine, National Cheng Kung University Hospital, College, Tainan 700, Taiwan.
Lee YC; Tainan Municipal Hospital, Tainan, Taiwan.
Li CY; Department of Public Health, College of Medicine, National Cheng Kung University, Tainan 700, Taiwan.; Department of Public Health, College of Public Health, China Medical University, Taichung 404, Taiwan.; Department of Healthcare Administration, College of Medical and Health Science, Asia University, Taichung 413, Taiwan.
Lee YL; Department of Oncology, Tainan Hospital, Ministry of Health and Welfare, Tainan 700, Taiwan.
Chen BL; College of Intelligence, National Taichung University of Science and Technology, Taichung 404, Taiwan.
Źródło:: Medicina (Kaunas, Lithuania) [Medicina (Kaunas)] 2020 Apr 27; Vol. 56 (5). Date of Electronic Publication: 2020 Apr 27.
Typ publikacji:: Systematic Review; Review
Język:: English
Imprint Name(s):: Publication: 2018- : Basel, Switzerland : MDPI
Original Publication: Kaunas : Lietuvos gydytojų sąjunga
MeSH Terms:: BRCA1 Protein/*analysis
BRCA2 Protein/*analysis
Lung Neoplasms/*blood
Adult ; Aged ; BRCA1 Protein/blood ; BRCA2 Protein/blood ; Female ; Genetic Predisposition to Disease ; Humans ; Incidence ; Mass Screening/methods ; Middle Aged ; Odds Ratio ; Retrospective Studies
References:: Hered Cancer Clin Pract. 2017 May 25;15:7. (PMID: 28559958)
Nat Commun. 2019 Jan 23;10(1):397. (PMID: 30674894)
Cell. 2002 Jan 25;108(2):171-82. (PMID: 11832208)
Oncologist. 2016 Jul;21(7):869-74. (PMID: 27306910)
Genet Med. 2015 Feb;17(2):117-24. (PMID: 25010056)
Prostate. 2019 Jun;79(8):880-895. (PMID: 30900310)
BMC Gastroenterol. 2019 Feb 4;19(1):21. (PMID: 30717682)
J Natl Cancer Inst. 2002 Sep 18;94(18):1365-72. (PMID: 12237282)
Cancer. 2015 Jan 15;121(2):269-75. (PMID: 25224030)
Lancet. 1994 Mar 19;343(8899):692-5. (PMID: 7907678)
Gynecol Oncol. 2015 May;137(2):343-50. (PMID: 25725131)
N Engl J Med. 1997 May 15;336(20):1401-8. (PMID: 9145676)
Fam Cancer. 2012 Jun;11(2):235-42. (PMID: 22187320)
Cancer Discov. 2018 Mar;8(3):256-257. (PMID: 29382645)
J Natl Cancer Inst. 2018 Nov 1;110(11):1178-1189. (PMID: 30380096)
J Natl Cancer Inst. 1999 Aug 4;91(15):1310-6. (PMID: 10433620)
Eur J Cancer. 1999 Aug;35(8):1248-57. (PMID: 10615237)
Cancer Manag Res. 2018 Aug 10;10:2553-2562. (PMID: 30127642)
Int J Cancer. 2018 Jun 1;142(11):2263-2272. (PMID: 29330845)
J Med Genet. 2005 Sep;42(9):711-9. (PMID: 16141007)
Nat Rev Cancer. 2011 Dec 23;12(1):68-78. (PMID: 22193408)
Br J Cancer. 2010 Sep 28;103(7):1103-8. (PMID: 20877337)
Am J Hum Genet. 2001 Mar;68(3):700-10. (PMID: 11179017)
J Natl Cancer Inst. 2002 Sep 18;94(18):1358-65. (PMID: 12237281)
Hered Cancer Clin Pract. 2019 Jan 3;17:1. (PMID: 30622657)
JAMA Oncol. 2018 Jun 1;4(6):872-874. (PMID: 29710070)
Contributed Indexing:: Keywords: BRCA1; BRCA2; lung cancer; meta-analysis
Substance Nomenclature:: 0 (BRCA1 Protein)
0 (BRCA1 protein, human)
0 (BRCA2 Protein)
0 (BRCA2 protein, human)
Entry Date(s):: Date Created: 20200501 Date Completed: 20210108 Latest Revision: 20240229
Update Code:: 20240229
PubMed Central ID:: PMC7279251
DOI:: 10.3390/medicina56050212
PMID:: 32349445
: Recenzja

Full Text Finder

Background and objective: BRCA1 and BRCA2 are associated with many cancer types in addition to hereditary breast and ovarian cancers. However, their relation to lung cancer remains to be explored. Materials and Methods: Observation studies were systematically reviewed to explore the association of BRCA1 or BRCA2 with lung cancer. PubMed, MEDLINE [EBSCOhost], and relevant articles published up to 7 January 2020 were searched. Odd ratio (OR), standardized morbidity rate (SMR), and cancer-specific standardized incidence ratios (SIRs) were pooled together as relative risk (RR) estimates (95% confidence interval [CI], 0.66-1.40). Results: Thirteen studies were included for analysis. Results showed that the RR of BRCA2 is 0.76 (95% CI, 0.48-1.19), the overall RR is 0.96 (95% CI, 0.66-1.40), and that of BRCA1 is 0.66 (95% CI, 0.41-1.05), indicating that it was not associated with lung cancer. Conclusion: With the limitation of the retrospective study design and severe heterogeneity, these results inform clinicians and relevant families that BRCA1 and BRCA2 mutation carriers have no increased risk of lung cancer.
Competing Interests: The authors declare no conflict of interest.

Informacja